Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

A new target for fetal hemoglobin reactivation.

Rivers A, Molokie R, Lavelle D.

Haematologica. 2019 Dec;104(12):2325-2327. doi: 10.3324/haematol.2019.230904. No abstract available.

2.

Sensitivities to Thermal and Mechanical Stimuli: Adults with Sickle Cell Disease Compared to Healthy, Pain-free African American Controls.

Molokie RE, Wang ZJ, Yao Y, Powell-Roach KL, Schlaeger JM, Suarez ML, Shuey DA, Angulo V, Carrasco J, Ezenwa MO, Fillingim RB, Wilkie DJ.

J Pain. 2019 Nov 13. pii: S1526-5900(19)30852-1. doi: 10.1016/j.jpain.2019.11.002. [Epub ahead of print]

PMID:
31733363
3.

A Stepped-Wedge Randomized Controlled Trial: Effects of eHealth Interventions for Pain Control among Adults with Cancer in Hospice.

Wilkie DJ, Yao Y, Ezenwa MO, Suarez ML, Dyal BW, Gill A, Hipp T, Shea R, Miller J, Frank K, Nardi N, Murray M, Glendenning J, Perez J, Carrasco JD, Shuey D, Angulo V, McCurry T, Martin J, Butler A, Wang ZJ, Molokie RE.

J Pain Symptom Manage. 2019 Nov 8. pii: S0885-3924(19)30645-1. doi: 10.1016/j.jpainsymman.2019.10.028. [Epub ahead of print]

PMID:
31711969
4.

Vasopressin SNP pain factors and stress in sickle cell disease.

Powell-Roach KL, Yao Y, Jhun EH, He Y, Suarez ML, Ezenwa MO, Molokie RE, Wang ZJ, Wilkie DJ.

PLoS One. 2019 Nov 11;14(11):e0224886. doi: 10.1371/journal.pone.0224886. eCollection 2019.

5.

A QST-based Pain Phenotype in Adults With Sickle Cell Disease: Sensitivity and Specificity of Quality Descriptors.

Dyal BW, Ezenwa MO, Yoon SL, Fillingim RB, Yao Y, Schlaeger JM, Suarez ML, Wang ZJ, Molokie RE, Wilkie DJ.

Pain Pract. 2019 Sep 25. doi: 10.1111/papr.12841. [Epub ahead of print]

PMID:
31553824
6.

Patients and Caregivers Rate the PAINReportIt Wireless Internet-Enabled Tablet as a Method for Reporting Pain During End-of-Life Cancer Care.

Schoppee TM, Dyal BW, Scarton L, Ezenwa MO, Singh P, Yao Y, Suarez ML, Wang ZJ, Molokie RE, Wilkie DJ.

Cancer Nurs. 2019 Sep 27. doi: 10.1097/NCC.0000000000000743. [Epub ahead of print]

PMID:
31517649
7.

Thermal and mechanical quantitative sensory testing values among healthy African American adults.

Powell-Roach KL, Yao Y, Rutherford JN, Schlaeger JM, Patil CL, Suarez ML, Shuey D, Angulo V, Carrasco J, Ezenwa MO, Fillingim RB, Wang ZJ, Molokie RE, Wilkie DJ.

J Pain Res. 2019 Aug 9;12:2511-2527. doi: 10.2147/JPR.S211855. eCollection 2019.

8.

Randomized clinical trial of computerized PAINRelieveIt® for patients with sickle cell disease: PAINReportIt® and PAINUCope®.

Dyal BW, Ezenwa MO, Yao Y, Molokie RE, Wang ZJ, Ballas SK, Suarez ML, Wilkie DJ.

Patient Educ Couns. 2020 Jan;103(1):136-144. doi: 10.1016/j.pec.2019.08.021. Epub 2019 Aug 17.

PMID:
31451364
9.

Keys to Recruiting and Retaining Seriously Ill African Americans With Sickle Cell Disease in Longitudinal Studies: Respectful Engagement and Persistence.

Suarez ML, Schlaeger JM, Angulo V, Shuey DA, Carrasco J, Roach KL, Ezenwa MO, Yao Y, Wang ZJ, Molokie RE, Wilkie DJ.

Am J Hosp Palliat Care. 2019 Aug 8:1049909119868657. doi: 10.1177/1049909119868657. [Epub ahead of print]

PMID:
31394904
10.

Kidney ultrasound findings according to kidney function in sickle cell anemia.

Patel R, Kang S, Valeshabad AK, Shah BN, Han J, Gowhari M, Molokie RE, Xie K, Lash JP, Gordeuk VR, Saraf SL.

Am J Hematol. 2019 Nov;94(11):E288-E291. doi: 10.1002/ajh.25602. Epub 2019 Aug 18. No abstract available.

PMID:
31379007
11.

Relationship of Pain Quality Descriptors and Quantitative Sensory Testing: Sickle Cell Disease.

Dyal BW, Ezenwa MO, Yoon SL, Fillingim RB, Yao Y, Schlaeger JM, Suarez ML, Wang ZJ, Molokie RE, Wilkie DJ.

Nurs Res. 2019 Sep/Oct;68(5):365-373. doi: 10.1097/NNR.0000000000000375.

PMID:
31283720
12.

Dendrimer-Based Platform for Effective Capture of Tumor Cells after TGFβ1-Induced Epithelial-Mesenchymal Transition.

Myung JH, Cha A, Tam KA, Poellmann M, Borgeat A, Sharifi R, Molokie RE, Votta-Velis G, Hong S.

Anal Chem. 2019 Jul 2;91(13):8374-8382. doi: 10.1021/acs.analchem.9b01181. Epub 2019 Jun 19.

PMID:
31247718
13.

Neuropathic Pain Screening: Construct Validity in Patients With Sickle Cell Disease.

Powell-Roach K, Yao Y, Ezenwa MO, Schlaeger JM, Suarez ML, Molokie RE, Wang ZJ, Wilkie DL.

West J Nurs Res. 2019 Mar 22:193945919836446. doi: 10.1177/0193945919836446. [Epub ahead of print]

PMID:
30900520
14.

Beta2-Adrenergic Receptor Polymorphisms and Haplotypes Associate With Chronic Pain in Sickle Cell Disease.

Jhun EH, Sadhu N, Hu X, Yao Y, He Y, Wilkie DJ, Molokie RE, Wang ZJ.

Front Pharmacol. 2019 Feb 7;10:84. doi: 10.3389/fphar.2019.00084. eCollection 2019.

15.

The morbidity and mortality of end stage renal disease in sickle cell disease.

Viner M, Zhou J, Allison D, Han J, Molokie RE, Jain S, Gowhari M, Gordeuk VR, Calip G, Saraf SL.

Am J Hematol. 2019 May;94(5):E138-E141. doi: 10.1002/ajh.25439. Epub 2019 Mar 1. No abstract available.

PMID:
30773675
16.

"Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia.

Akingbola TS, Tayo BO, Ezekekwu CA, Sonubi O, Zhang X, Saraf SL, Molokie R, Hsu LL, Han J, Cooper RS, Gordeuk VR.

Am J Hematol. 2019 Apr;94(4):E112-E115. doi: 10.1002/ajh.25412. Epub 2019 Feb 6. No abstract available.

PMID:
30663794
17.

Integration of neuropsychology services in a sickle cell clinic and subsequent healthcare use for pain crises.

Janecek JK, Dorociak KE, Piper LE, Kelleher T, Pliskin NH, Gowhari M, Molokie RE.

Clin Neuropsychol. 2019 Oct;33(7):1195-1211. doi: 10.1080/13854046.2018.1535664. Epub 2018 Nov 24.

PMID:
30472925
18.

Use of metformin in patients with sickle cell disease.

Han J, Saraf SL, Molokie RE, Gordeuk VR.

Am J Hematol. 2019 Jan;94(1):E13-E15. doi: 10.1002/ajh.25313. Epub 2018 Nov 9. No abstract available.

PMID:
30328140
19.

High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease.

Han J, Saraf SL, Gowhari M, Jain S, Molokie RE, Gordeuk VR.

Am J Hematol. 2019 Jan;94(1):E5-E7. doi: 10.1002/ajh.25311. Epub 2018 Oct 31. No abstract available.

PMID:
30299555
20.

HMOX1 and acute kidney injury in sickle cell anemia.

Saraf SL, Viner M, Rischall A, Raslan R, Shah BN, Zhang X, Han J, Gowhari M, Jain S, Molokie RE, Machado RF, Lash JP, Gordeuk VR.

Blood. 2018 Oct 11;132(15):1621-1625. doi: 10.1182/blood-2018-05-853929. Epub 2018 Aug 23. No abstract available.

21.

Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.

Rivers A, Vaitkus K, Jagadeeswaran R, Ruiz MA, Ibanez V, Ciceri F, Cavalcanti F, Molokie RE, Saunthararajah Y, Engel JD, DeSimone J, Lavelle D.

Exp Hematol. 2018 Nov;67:60-64.e2. doi: 10.1016/j.exphem.2018.08.003. Epub 2018 Aug 17.

PMID:
30125603
22.

Glucocorticoid receptor single nucleotide polymorphisms are associated with acute crisis pain in sickle cell disease.

Jhun EH, Sadhu N, Yao Y, He Y, Molokie RE, Wilkie DJ, Wang ZJ.

Pharmacogenomics. 2018 Aug 1;19(13):1003-1011. doi: 10.2217/pgs-2018-0064. Epub 2018 Aug 6.

23.

Genetic variants of GCH1 associate with chronic and acute crisis pain in African Americans with sickle cell disease.

Sadhu N, Jhun EH, Yao Y, He Y, Molokie RE, Wilkie DJ, Wang ZJ.

Exp Hematol. 2018 Oct;66:42-49. doi: 10.1016/j.exphem.2018.07.004. Epub 2018 Jul 19.

24.

Bedside ultrasound as a predictive tool for acute chest syndrome in sickle cell patients.

Colla JS, Kotini-Shah P, Soppet S, Chen YF, Molokie R, Prajapati P, Prendergast HM.

Am J Emerg Med. 2018 Oct;36(10):1855-1861. doi: 10.1016/j.ajem.2018.07.006. Epub 2018 Jul 3.

PMID:
30017686
25.

Risk factors for vitamin D deficiency in sickle cell disease.

Han J, Zhang X, Saraf SL, Gowhari M, Molokie RE, Hassan J, Jain S, Shah BN, Abbasi T, Machado RF, Gordeuk VR.

Br J Haematol. 2018 Jun;181(6):828-835. doi: 10.1111/bjh.15270. Epub 2018 May 16.

26.

Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease.

Saraf SL, Oh AL, Patel PR, Sweiss K, Koshy M, Campbell-Lee S, Gowhari M, Jain S, Peace D, Quigley JG, Khan I, Molokie RE, Mahmud N, Gordeuk VR, Rondelli D.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1759-1765. doi: 10.1016/j.bbmt.2018.03.031. Epub 2018 Apr 12.

27.

Association of Cardiomyopathy With MYBPC3 D389V and MYBPC3Δ25bpIntronic Deletion in South Asian Descendants.

Viswanathan SK, Puckelwartz MJ, Mehta A, Ramachandra CJA, Jagadeesan A, Fritsche-Danielson R, Bhat RV, Wong P, Kandoi S, Schwanekamp JA, Kuffel G, Pesce LL, Zilliox MJ, Durai UNB, Verma RS, Molokie RE, Suresh DP, Khoury PR, Thomas A, Sanagala T, Tang HC, Becker RC, Knöll R, Shim W, McNally EM, Sadayappan S.

JAMA Cardiol. 2018 Jun 1;3(6):481-488. doi: 10.1001/jamacardio.2018.0618.

28.

Transient receptor potential polymorphism and haplotype associate with crisis pain in sickle cell disease.

Jhun EH, Hu X, Sadhu N, Yao Y, He Y, Wilkie DJ, Molokie RE, Wang ZJ.

Pharmacogenomics. 2018 Apr;19(5):401-411. doi: 10.2217/pgs-2017-0198. Epub 2018 Apr 5.

29.

The AVPR1A Gene and Its Single Nucleotide Polymorphism rs10877969: A Literature Review of Associations with Health Conditions and Pain.

Roach KL, Hershberger PE, Rutherford JN, Molokie RE, Wang ZJ, Wilkie DJ.

Pain Manag Nurs. 2018 Aug;19(4):430-444. doi: 10.1016/j.pmn.2018.01.003. Epub 2018 Mar 2. Review.

30.

Differences in Sensory Pain, Expectation, and Satisfaction Reported by Outpatients with Cancer or Sickle Cell Disease.

Ezenwa MO, Molokie RE, Wang ZJ, Yao Y, Suarez ML, Dyal B, Abudawood K, Wilkie DJ.

Pain Manag Nurs. 2018 Aug;19(4):322-332. doi: 10.1016/j.pmn.2017.11.010. Epub 2018 Mar 1.

31.

Program expansion of a day hospital dedicated to manage sickle cell pain.

Han J, Saraf SL, Kavoliunaite L, Jain S, Hassan J, Hsu LL, Molokie RE, Gordeuk VR, Gowhari M.

Am J Hematol. 2018 Jan;93(1):E20-E21. doi: 10.1002/ajh.24938. Epub 2017 Oct 31. No abstract available.

32.

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y.

PLoS Med. 2017 Sep 7;14(9):e1002382. doi: 10.1371/journal.pmed.1002382. eCollection 2017 Sep.

33.

Management of Sickle Cell Pain Using Pregabalin: A Pilot Study.

Schlaeger JM, Molokie RE, Yao Y, Suarez ML, Golembiewski J, Wilkie DJ, Votta-Velis G.

Pain Manag Nurs. 2017 Dec;18(6):391-400. doi: 10.1016/j.pmn.2017.07.003. Epub 2017 Aug 23.

PMID:
28843636
34.

Opioid doses and acute care utilization outcomes for adults with sickle cell disease: ED versus acute care unit.

Molokie RE, Montminy C, Dionisio C, Farooqui MA, Gowhari M, Yao Y, Suarez ML, Ezenwa MO, Schlaeger JM, Wang ZJ, Wilkie DJ.

Am J Emerg Med. 2018 Jan;36(1):88-92. doi: 10.1016/j.ajem.2017.07.037. Epub 2017 Jul 13.

PMID:
28802541
35.

Erythropoiesis-stimulating agents in sickle cell anaemia.

Han J, Zhou J, Kondragunta V, Zhang X, Molokie RE, Gowhari M, Hassan J, Jain S, Calip GS, Gordeuk VR, Saraf SL.

Br J Haematol. 2018 Aug;182(4):602-605. doi: 10.1111/bjh.14846. Epub 2017 Jul 27. No abstract available.

36.

Performance validity testing in a clinical sample of adults with sickle cell disease.

Dorociak KE, Schulze ET, Piper LE, Molokie RE, Janecek JK.

Clin Neuropsychol. 2018 Jan;32(1):81-97. doi: 10.1080/13854046.2017.1339830. Epub 2017 Jun 15.

PMID:
28632024
37.

Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways.

Han J, Zhang X, Oderinde J, Saraf SL, Gowhari M, Hassan J, Jain S, Gordeuk VR, Molokie RE.

Haematologica. 2017 Aug;102(8):e282-e284. doi: 10.3324/haematol.2017.169128. Epub 2017 May 4. No abstract available.

38.

Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease.

Jagadeeswaran R, Vazquez BA, Thiruppathi M, Ganesh BB, Ibanez V, Cui S, Engel JD, Diamond AM, Molokie RE, DeSimone J, Lavelle D, Rivers A.

Exp Hematol. 2017 Jun;50:46-52. doi: 10.1016/j.exphem.2017.02.003. Epub 2017 Feb 24.

39.

Efficacy and safety of long-term RN-1 treatment to increase HbF in baboons.

Ibanez V, Vaitkus K, Rivers A, Molokie R, Cui S, Engel JD, DeSimone J, Lavelle D.

Blood. 2017 Jan 12;129(2):260-263. doi: 10.1182/blood-2016-10-746727. Epub 2016 Dec 1. No abstract available.

40.

IL1A rs1800587 associates with chronic noncrisis pain in sickle cell disease.

Hu X, Jhun EH, Yao Y, He Y, Molokie RE, Wilkie DJ, Wang ZJ.

Pharmacogenomics. 2016 Dec;17(18):1999-2006. Epub 2016 Nov 24.

41.

CaMKIIα underlies spontaneous and evoked pain behaviors in Berkeley sickle cell transgenic mice.

He Y, Chen Y, Tian X, Yang C, Lu J, Xiao C, DeSimone J, Wilkie DJ, Molokie RE, Wang ZJ.

Pain. 2016 Dec;157(12):2798-2806.

42.

Patterns of opioid use in sickle cell disease.

Han J, Saraf SL, Zhang X, Gowhari M, Molokie RE, Hassan J, Alhandalous C, Jain S, Younge J, Abbasi T, Machado RF, Gordeuk VR.

Am J Hematol. 2016 Nov;91(11):1102-1106. doi: 10.1002/ajh.24498. Epub 2016 Aug 8.

43.

APOL1, α-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia.

Saraf SL, Shah BN, Zhang X, Han J, Tayo BO, Abbasi T, Ostrower A, Guzman E, Molokie RE, Gowhari M, Hassan J, Jain S, Cooper RS, Machado RF, Lash JP, Gordeuk VR.

Haematologica. 2017 Jan;102(1):e1-e6. doi: 10.3324/haematol.2016.154153. Epub 2016 Sep 22. No abstract available.

44.

Implementing the PAIN RelieveIt Randomized Controlled Trial in Hospice Care: Mechanisms for Success and Meeting PCORI Methodology Standards.

Ezenwa MO, Suarez ML, Carrasco JD, Hipp T, Gill A, Miller J, Shea R, Shuey D, Zhao Z, Angulo V, McCurry T, Martin J, Yao Y, Molokie RE, Wang ZJ, Wilkie DJ.

West J Nurs Res. 2017 Jul;39(7):924-941. doi: 10.1177/0193945916668328. Epub 2016 Sep 12.

PMID:
27621272
45.

PKCδ-targeted intervention relieves chronic pain in a murine sickle cell disease model.

He Y, Wilkie DJ, Nazari J, Wang R, Messing RO, DeSimone J, Molokie RE, Wang ZJ.

J Clin Invest. 2016 Aug 1;126(8):3053-7. doi: 10.1172/JCI86165. Epub 2016 Jun 27.

46.

Coping with Pain in the Face of Healthcare Injustice in Patients with Sickle Cell Disease.

Ezenwa MO, Yao Y, Molokie RE, Wang ZJ, Mandernach MW, Suarez ML, Wilkie DJ.

J Immigr Minor Health. 2017 Dec;19(6):1449-1456. doi: 10.1007/s10903-016-0432-0.

47.

Pain Intensity and Misconceptions Among Hospice Patients With Cancer and Their Caregivers: Status After 2 Decades.

Wilkie DJ, Ezenwa MO, Yao Y, Gill A, Hipp T, Shea R, Miller J, Carrasco J, Shuey D, Zhao Z, Angulo V, Suarez ML, McCurry T, Martin J, Molokie RE, Wang ZW.

Am J Hosp Palliat Care. 2017 May;34(4):318-324. doi: 10.1177/1049909116639612. Epub 2016 Mar 22.

PMID:
27006391
48.

Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb Sβ+-thalassemia sickle cell disease.

Rosenberg A, Selounski V, Wardak H, Han J, Gowhari M, Hassan J, Jain S, Molokie RE, Gordeuk VR, Saraf SL.

Am J Hematol. 2016 Jun;91(6):E316-7. doi: 10.1002/ajh.24363. Epub 2016 Apr 24. No abstract available.

49.

Toward understanding family-related characteristics of young adults with sickle-cell disease or sickle-cell trait in the USA.

Hershberger PE, Gallo AM, Molokie R, Thompson AA, Suarez ML, Yao Y, Dallas CM, Wilkie DJ.

J Clin Nurs. 2016 Jun;25(11-12):1587-97. doi: 10.1111/jocn.13144. Epub 2016 Mar 11.

50.

A randomized controlled pilot study feasibility of a tablet-based guided audio-visual relaxation intervention for reducing stress and pain in adults with sickle cell disease.

Ezenwa MO, Yao Y, Engeland CG, Molokie RE, Wang ZJ, Suarez ML, Wilkie DJ.

J Adv Nurs. 2016 Jun;72(6):1452-63. doi: 10.1111/jan.12895. Epub 2016 Jan 15.

PMID:
26768753

Supplemental Content

Loading ...
Support Center